Identification of Phosphoglycerate Kinase 1 (PGK1) as a reference gene for quantitative gene expression measurements in human blood RNA. — ME/CFS Atlas
E3 PreliminaryModerate confidencePEM not requiredMethods-PaperPeer-reviewedReviewed
Standard · 3 min
Identification of Phosphoglycerate Kinase 1 (PGK1) as a reference gene for quantitative gene expression measurements in human blood RNA.
Falkenberg, Virginia R, Whistler, Toni, Murray, Janna' R et al. · BMC research notes · 2011 · DOI
Quick Summary
Researchers studying ME/CFS need reliable ways to measure gene activity in blood samples. This study found that a gene called PGK1 is a stable and reliable 'reference point' for comparing gene measurements across different blood collection methods and sample types. Using a single stable reference gene like PGK1 makes it easier for scientists to get accurate, comparable results when searching for blood-based biomarkers of ME/CFS.
Why It Matters
Standardized gene expression measurement techniques are essential for identifying and validating ME/CFS biomarkers. This work establishes methodological consistency that allows blood-based gene expression studies to be reliably compared across different laboratories and collection protocols, accelerating biomarker discovery and validation in ME/CFS research.
Observed Findings
PGK1 was identified as an optimal and stable reference gene for normalization in both whole blood RNA and PBMC RNA samples.
RPLP0 was identified as an optimal supplementary reference gene specifically for PBMC RNA analysis.
PPIB was identified as an optimal supplementary reference gene specifically for whole blood RNA analysis.
A single stable reference gene is sufficient for accurate normalization in qRT-PCR studies, rather than requiring multiple genes.
Use of optimal reference genes improves the ability to compare gene expression results between whole blood and PBMC samples and across different collection methods.
Inferred Conclusions
PGK1 is a reliable reference gene for quantitative gene expression studies in blood samples relevant to ME/CFS research.
Optimal reference gene selection improves standardization and comparability of gene expression results across different collection and processing methods.
Large-scale molecular epidemiologic studies using blood RNA will benefit from these standardized normalization approaches in biomarker discovery efforts.
Remaining Questions
How do these reference genes perform in ME/CFS patient samples specifically compared to healthy controls?
What This Study Does Not Prove
This study does not identify any disease biomarkers or genes associated with ME/CFS pathology itself—it only establishes technical standards for measuring gene expression reliably. It does not prove that any particular gene is dysregulated in ME/CFS patients, nor does it validate biomarker utility in diagnosis or prognosis.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.